Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick Sells 1,383 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kymera Therapeutics Trading Down 3.8 %

Kymera Therapeutics stock opened at $30.17 on Tuesday. Kymera Therapeutics, Inc. has a 12 month low of $29.16 and a 12 month high of $53.27. The stock’s 50 day simple moving average is $38.81 and its two-hundred day simple moving average is $43.66. The firm has a market cap of $1.95 billion, a PE ratio of -12.89 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA boosted its position in Kymera Therapeutics by 11.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after purchasing an additional 47,507 shares in the last quarter. Eventide Asset Management LLC lifted its position in shares of Kymera Therapeutics by 9.9% during the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock valued at $24,039,000 after buying an additional 45,803 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $650,000. JPMorgan Chase & Co. lifted its position in shares of Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after buying an additional 95,547 shares in the last quarter. Finally, Natixis Advisors LLC purchased a new position in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $681,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Stephens restated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Morgan Stanley increased their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. BTIG Research began coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.